{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:10:25Z","timestamp":1790284225826,"version":"4.1.0"},"reference-count":88,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.trecan.2026.03.004","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T03:43:31Z","timestamp":1776829411000},"page":"553-568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeting cyclin-dependent kinases in cancer: emerging therapeutics and clinical strategies"],"prefix":"10.1016","volume":"12","author":[{"given":"Harold N.","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A.","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2026.03.004_bb0005","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc1495","article-title":"CDK4 and CDK6 kinases: from basic science to cancer therapy","volume":"375","author":"Fassl","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.trecan.2026.03.004_bb0010","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.3390\/ijms21061960","article-title":"The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer","volume":"21","author":"Ding","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.trecan.2026.03.004_bb0015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41392-024-02080-z","article-title":"Cyclin-dependent protein kinases and cell cycle regulation in biology and disease","volume":"10","author":"Pellarin","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.trecan.2026.03.004_bb0020","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ccell.2021.03.010","article-title":"Targeting cell-cycle machinery in cancer","volume":"39","author":"Suski","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.03.004_bb0025","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ccell.2020.03.010","article-title":"Mechanisms of sensitivity and resistance to CDK inhibition","volume":"37","author":"Alvarez-Fernandez","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.03.004_bb0030","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/s12935-022-02747-z","article-title":"A review on the role of cyclin dependent kinases in cancers","volume":"22","author":"Ghafouri-Fard","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.trecan.2026.03.004_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110448","article-title":"CDK\/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities","volume":"38","author":"Knudsen","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.trecan.2026.03.004_bb0040","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.03.004_bb0045","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.23.00137","article-title":"Overall survival with palbociclib plus letrozole in advanced breast cancer","volume":"42","author":"Slamon","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.03.004_bb0050","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41523-021-00289-7","article-title":"Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups","volume":"7","author":"Johnston","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.trecan.2026.03.004_bb0055","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.annonc.2021.05.353","article-title":"Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival","volume":"32","author":"Slamon","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.03.004_bb0060","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy\u2014MONARCH 2: a randomized clinical trial","volume":"6","author":"Sledge","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.trecan.2026.03.004_bb0065","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with ribociclib plus endocrine therapy in breast cancer","volume":"381","author":"Im","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.03.004_bb0070","article-title":"Palbociclib in patients with head and neck cancer and other tumors with CDKN2A alterations: results from the targeted agent and profiling utilization registry study","volume":"8","author":"Worden","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.trecan.2026.03.004_bb0075","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1158\/1078-0432.CCR-15-1421","article-title":"Mechanistic investigation of bone marrow suppression associated with palbociclib and its differentiation from cytotoxic chemotherapies","volume":"22","author":"Hu","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.03.004_bb0080","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.03.004_bb0085","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1158\/1541-7786.MCR-17-0468","article-title":"Competitive kinase enrichment proteomics reveals that abemaciclib inhibits GSK3\u03b2 and activates WNT signaling","volume":"16","author":"Cousins","year":"2018","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.trecan.2026.03.004_bb0090","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41401-020-0416-4","article-title":"Intrinsic and acquired resistance to CDK4\/6 inhibitors and potential overcoming strategies","volume":"42","author":"Xu","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.trecan.2026.03.004_bb0095","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s43018-024-00893-z","article-title":"Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer","volume":"6","author":"Asciolla","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.trecan.2026.03.004_bb0100","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.molcel.2020.08.020","article-title":"Integrating old and new paradigms of G1\/S control","volume":"80","author":"Rubin","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.trecan.2026.03.004_bb0105","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1158\/2159-8290.CD-19-1390","article-title":"The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4\/6 inhibitors in patients with hormone receptor\u2013positive metastatic breast cancer","volume":"10","author":"Wander","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2026.03.004_bb0110","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1158\/1541-7786.MCR-23-0045","article-title":"Significance of RB loss in unlocking phenotypic plasticity in advanced cancers","volume":"21","author":"Venkadakrishnan","year":"2023","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.trecan.2026.03.004_bb0115","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1038\/s41388-018-0368-z","article-title":"Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer","volume":"37","author":"Brough","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.trecan.2026.03.004_bb0120","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1016\/j.cell.2023.05.013","article-title":"Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity","volume":"186","author":"Arora","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2026.03.004_bb0125","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.celrep.2018.01.022","article-title":"Targeting the vulnerability of RB tumor suppressor loss in triple-negative breast cancer","volume":"22","author":"Witkiewicz","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.trecan.2026.03.004_bb0130","doi-asserted-by":"crossref","first-page":"5258","DOI":"10.1038\/s41467-022-32828-6","article-title":"High p16 expression and heterozygous RB1 loss are biomarkers for CDK4\/6 inhibitor resistance in ER+ breast cancer","volume":"13","author":"Palafox","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.03.004_bb0135","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.1038\/oncsis.2017.5","article-title":"p16 controls epithelial cell growth and suppresses carcinogenesis through mechanisms that do not require RB1 function","volume":"6","author":"Sen","year":"2017","journal-title":"Oncogenesis"},{"key":"10.1016\/j.trecan.2026.03.004_bb0140","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1158\/1535-7163.MCT-18-0755","article-title":"Direct CDKN2 modulation of CDK4 alters target engagement of CDK4 inhibitor drugs","volume":"18","author":"Green","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.trecan.2026.03.004_bb0145","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.ccell.2017.11.006","article-title":"Genomic aberrations that activate D-type cyclins are associated with enhanced sensitivity to the CDK4 and CDK6 inhibitor abemaciclib","volume":"32","author":"Gong","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.03.004_bb0150","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-15-0728","article-title":"Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor-positive breast cancer","volume":"76","author":"Herrera-Abreu","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.03.004_bb0155","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1158\/0008-5472.CAN-18-1235","article-title":"Low-molecular-weight cyclin E in human cancer: cellular consequences and opportunities for targeted therapies","volume":"78","author":"Caruso","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.03.004_bb0160","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.4161\/cc.9.12.11988","article-title":"Ubiquitylation and proteasomal degradation of the p21Cip1, p27Kip1 and p57Kip2 CDK inhibitors","volume":"9","author":"Lu","year":"2010","journal-title":"Cell Cycle"},{"key":"10.1016\/j.trecan.2026.03.004_bb0165","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s43018-021-00174-z","article-title":"Distinct CDK6 complexes determine tumor cell response to CDK4\/6 inhibitors and degraders","volume":"2","author":"Wu","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.trecan.2026.03.004_bb0170","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.ccell.2018.11.006","article-title":"Loss of the FAT1 tumor suppressor promotes resistance to CDK4\/6 inhibitors via the Hippo pathway","volume":"34","author":"Li","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.03.004_bb0175","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1016\/j.celrep.2019.02.023","article-title":"MicroRNA-mediated suppression of the TGF-\u03b2 pathway confers transmissible and reversible CDK4\/6 inhibitor resistance","volume":"26","author":"Cornell","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.trecan.2026.03.004_bb0180","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2013.07.012","article-title":"A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis","volume":"24","author":"Kollmann","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.03.004_bb0185","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1158\/2159-8290.CD-20-1726","article-title":"INK4 tumor suppressor proteins mediate resistance to CDK4\/6 kinase inhibitors","volume":"12","author":"Li","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2026.03.004_bb0190","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","article-title":"Targeting CDK4 and CDK6 in cancer","volume":"22","author":"Goel","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.trecan.2026.03.004_bb0195","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1158\/1078-0432.CCR-14-2955","article-title":"CDK4 amplification reduces sensitivity to CDK4\/6 inhibition in fusion-positive rhabdomyosarcoma","volume":"21","author":"Olanich","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.03.004_bb0200","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3389\/fphar.2019.01176","article-title":"Akt regulated phosphorylation of GSK-3\u03b2\/cyclin D1, p21 and p27 contributes to cell proliferation through cell cycle progression from G1 to S\/G2M phase in low-dose arsenite exposed HaCat cells","volume":"10","author":"Chen","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.trecan.2026.03.004_bb0205","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1158\/1078-0432.CCR-08-0170","article-title":"Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma","volume":"15","author":"Kim","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.03.004_bb0210","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/s41467-019-09068-2","article-title":"Aberrant FGFR signaling mediates resistance to CDK4\/6 inhibitors in ER+ breast cancer","volume":"10","author":"Formisano","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.03.004_bb0215","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1038\/s41467-018-05914-x","article-title":"The prognostic effects of somatic mutations in ER-positive breast cancer","volume":"9","author":"Griffith","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.03.004_bb0220","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1158\/1078-0432.CCR-18-0372","article-title":"A combination CDK4\/6 and IGF1R inhibitor strategy for Ewing sarcoma","volume":"25","author":"Guenther","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.03.004_bb0225","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.18.00925","article-title":"Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor\u2013positive metastatic breast cancer","volume":"37","author":"Turner","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.03.004_bb0230","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.774845","article-title":"Cyclin E\/CDK2: DNA replication, replication stress and genomic instability","volume":"9","author":"Fagundes","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.trecan.2026.03.004_bb0235","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1158\/1078-0432.CCR-13-1337","article-title":"Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer","volume":"19","author":"Etemadmoghadam","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.03.004_bb0240","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41698-022-00311-6","article-title":"Co-targeting CDK2 and CDK 4\/6 overcomes resistance to aromatase and CDK4\/6 inhibitors in ER+ breast cancer","volume":"6","author":"Al-Qasem","year":"2022","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.trecan.2026.03.004_bb0245","doi-asserted-by":"crossref","first-page":"9056","DOI":"10.1021\/acs.jmedchem.1c00159","article-title":"Discovery of PF-06873600, a CDK2\/4\/6 inhibitor for the treatment of cancer","volume":"64","author":"Freeman-Cook","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.trecan.2026.03.004_bb0250","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.ccell.2021.08.009","article-title":"Expanding control of the tumor cell cycle with a CDK2\/4\/6 inhibitor","volume":"39","author":"Freeman-Cook","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.03.004_bb0255","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1038\/s44318-025-00402-7","article-title":"p53 regulates DREAM complex-mediated repression in a p21-independent manner","volume":"44","author":"Agrawal","year":"2025","journal-title":"EMBO J."},{"key":"10.1016\/j.trecan.2026.03.004_bb0260","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.ccell.2024.09.009","article-title":"Long-term breast cancer response to CDK4\/6 inhibition defined by TP53-mediated geroconversion","volume":"42","author":"Kudo","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.03.004_bb0265","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3390\/genes10030244","article-title":"MYC oncogene contributions to release of cell cycle brakes","volume":"10","author":"Garc\u00eda-Guti\u00e9rrez","year":"2019","journal-title":"Genes"},{"key":"10.1016\/j.trecan.2026.03.004_bb0270","doi-asserted-by":"crossref","first-page":"6687","DOI":"10.1158\/0008-5472.CAN-10-1383","article-title":"Tipping the balance: Cdk2 enables Myc to suppress senescence","volume":"70","author":"Hydbring","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.03.004_bb0275","doi-asserted-by":"crossref","first-page":"9056","DOI":"10.1021\/acs.jmedchem.1c00159","article-title":"Discovery of PF-06873600, a CDK2\/4\/6 inhibitor for the treatment of cancer","volume":"64","author":"Freeman-Cook","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.trecan.2026.03.004_bb0280","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1158\/1078-0432.CCR-24-2740","article-title":"First-in-human phase I\/IIa study of the first-in-class CDK2\/4\/6 inhibitor PF-06873600 alone or with endocrine therapy in patients with breast cancer","volume":"31","author":"Yap","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.03.004_bb0285","doi-asserted-by":"crossref","first-page":"PS16","DOI":"10.1158\/1538-7445.SABCS20-PS16-22","article-title":"Abstract PS16-22: targeting resistance to current CDK4\/6 therapies by RGT-419B, an inhibitor with optimized kinase activity spectrum","volume":"81","author":"Xie","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.03.004_bb0290","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS23-PO3-18-06","article-title":"Abstract PO3-18-06: first-in-human phase 1A study of RGT-419B, a next generation CDK4 inhibitor, in patients (pts) with hormone receptor positive (HR+) HER2- advanced\/metastatic breast cancer (ABC) who progressed on prior CDK4\/6 inhibitors (CDK4\/6i)","volume":"84","author":"Wander","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.03.004_bb0295","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.stem.2015.01.017","article-title":"CDK6 levels regulate quiescence exit in human hematopoietic stem cells","volume":"16","author":"Laurenti","year":"2015","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.trecan.2026.03.004_bb0300","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1182\/blood-2014-06-584417","article-title":"CDK6 as a key regulator of hematopoietic and leukemic stem cell activation","volume":"125","author":"Scheicher","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2026.03.004_bb0305","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1038\/sj.emboj.7601675","article-title":"Cdk6 blocks myeloid differentiation by interfering with Runx1 DNA binding and Runx1-C\/EBP\u03b1 interaction","volume":"26","author":"Fujimoto","year":"2007","journal-title":"EMBO J."},{"key":"10.1016\/j.trecan.2026.03.004_bb0310","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ccell.2025.02.006","article-title":"CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety","volume":"43","author":"Palmer","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.03.004_bb0315","doi-asserted-by":"crossref","first-page":"26085","DOI":"10.1021\/acs.jmedchem.5c02137","article-title":"Discovery of atirmociclib (PF-07220060): a potent and selective CDK4 inhibitor","volume":"68","author":"Gallego","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.trecan.2026.03.004_bb0320","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1200\/JCO.2023.41.16_suppl.3009","article-title":"First-in-human first-in-class phase 1\/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2\u2212 mBC who progressed on prior CDK4\/6 inhibitors and endocrine therapy","volume":"41","author":"Yap","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.03.004_bb0325","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1158\/1078-0432.CCR-16-0620","article-title":"Selective targeting of cyclin E1-amplified high-grade serous ovarian cancer by cyclin-dependent kinase 2 and AKT inhibition","volume":"23","author":"Au-Yeung","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.03.004_bb0330","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3390\/diagnostics10050279","article-title":"CCNE1 amplification as a predictive biomarker of chemotherapy resistance in epithelial ovarian cancer","volume":"10","author":"Gorski","year":"2020","journal-title":"Diagnostics"},{"key":"10.1016\/j.trecan.2026.03.004_bb0335","doi-asserted-by":"crossref","first-page":"6594","DOI":"10.1158\/1078-0432.CCR-18-1446","article-title":"Cyclin E overexpression sensitizes triple-negative breast cancer to Wee1 kinase inhibition","volume":"24","author":"Chen","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.03.004_bb0340","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1158\/1535-7163.MCT-11-0963","article-title":"Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells","volume":"11","author":"Caldon","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.trecan.2026.03.004_bb0345","article-title":"p16 expression confers sensitivity to CDK2 inhibitors","author":"Sine","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.trecan.2026.03.004_bb0350","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/s41467-025-56674-4","article-title":"Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle","volume":"16","author":"Kumarasamy","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.03.004_bb0355","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2023.41.16_suppl.3010","article-title":"First-in-human phase 1\/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4\/6 inhibitor resistant HR+\/HER2- breast cancer","volume":"41","author":"Yap","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.03.004_bb0360","doi-asserted-by":"crossref","first-page":"S495","DOI":"10.1016\/j.annonc.2024.08.685","article-title":"618MO Phase Ib\/II first-in-class novel combination trial of next generation CDK4-selective inhibitor PF-07220060 and next generation CDK2-selective inhibitor PF-07104091 in HR+ HER2- metastatic breast cancer and advanced solid tumors","volume":"35","author":"Yap","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.03.004_bb0365","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.2023.41.16_suppl.3095","article-title":"BLU-222, an oral, potent, and selective CDK2 inhibitor, in patients with advanced solid tumors: phase 1 monotherapy dose escalation","volume":"41","author":"Patel","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.03.004_bb0370","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1158\/0008-5472.CAN-24-2360","article-title":"Profiling the activity of the potent and highly selective CDK2 inhibitor BLU-222 reveals determinants of response in CCNE1-aberrant ovarian and endometrial tumors","volume":"85","author":"House","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.03.004_bb0375","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41467-025-67865-4","article-title":"CDK2 inhibitor BLU-222 synergizes with CDK4\/6 inhibitors in drug resistant breast cancers through p21\/p27 induction","volume":"17","author":"Luo","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.03.004_bb0380","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1200\/JCO.2024.42.16_suppl.1056","article-title":"BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and fulvestrant (FUL) in HR+\/HER2\u2212 breast cancer (BC)","volume":"42","author":"Juric","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.03.004_bb0385","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1158\/1538-7445.AM2023-1143","article-title":"Abstract 1143: development of a CDK2-selective small molecule inhibitor INCB123667 for the treatment of CCNE1hi breast cancers","volume":"83","author":"Chand","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.03.004_bb0390","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.1200\/JCO.2025.43.16_suppl.5603","article-title":"Interim safety and antitumor activity data from a phase 1 study of INCB123667, a selective CDK2 inhibitor, in patients with metastatic recurrent endometrial cancer","volume":"43","author":"Lorusso","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.03.004_bb0395","doi-asserted-by":"crossref","first-page":"18164","DOI":"10.1021\/acs.jmedchem.5c01478","article-title":"Discovery of AZD8421: a potent CDK2 inhibitor with selectivity against other CDK family members and the human kinome","volume":"68","author":"Ghosh","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.trecan.2026.03.004_bb0400","doi-asserted-by":"crossref","first-page":"S405","DOI":"10.1016\/j.annonc.2024.08.386","article-title":"439TiP AVZO-021-1001: a first-in-human open-label, multicenter phase I\/II dose-escalation and expansion study evaluating AVZO-021 in adult patients with advanced solid tumors","volume":"35","author":"Dowlati","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.03.004_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.116140","article-title":"Targeting CDK2 for cancer therapy","volume":"44","author":"Knudsen","year":"2025","journal-title":"Cell Rep."},{"key":"10.1016\/j.trecan.2026.03.004_bb0410","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1158\/2159-8290.CD-23-0954","article-title":"INX-315, a selective CDK2 inhibitor, induces cell cycle arrest and senescence in solid tumors","volume":"14","author":"Dietrich","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2026.03.004_bb0415","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41586-022-04638-9","article-title":"CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition","volume":"604","author":"Gallo","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.03.004_bb0420","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/s41388-025-03312-4","article-title":"Cyclin E1 overexpression sensitizes ovarian cancer cells to WEE1 and PLK1 inhibition","volume":"44","author":"Xi","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.trecan.2026.03.004_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114543","article-title":"14 (PB002): discovery of NKT3964: a first-in-class, highly potent and selective, orally bioavailable CDK2 PROTAC degrader for cancer therapy","volume":"211","author":"Geng","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.trecan.2026.03.004_bb0430","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejca.2024.114989","article-title":"511LBA (PB-511) LBA posters: selective targeting of cyclinE1 using molecular glue degraders in CCNE1 amplified solid malignancies","volume":"211","author":"Ilic-Widlund","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.trecan.2026.03.004_bb0435","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.chembiol.2025.03.006","article-title":"CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers","volume":"32","author":"Kwiatkowski","year":"2025","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.trecan.2026.03.004_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114993","article-title":"515LBA (PB-515) LBA Posters: CID-078, a first-in-class oral macrocycle cyclin A\/B-RxL inhibitor, demonstrates anti-tumor activity in E2F-driven cancers","author":"Evangelista","year":"2024","journal-title":"Eur. J. Cancer"}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803326000592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803326000592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T03:02:27Z","timestamp":1781060547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803326000592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":88,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2405803326000592"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2026.03.004","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting cyclin-dependent kinases in cancer: emerging therapeutics and clinical strategies","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2026.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}